The group's principal activity is to conduct research, develop, manufacture and marketing of medical products. The group develops haemoglobin-based artificial oxygen carriers, products thereof and an anti-aging cosmetic based on the oxygen carriers. The group also develops a long-term implantable glucose sensor, its by-products and sensors. During fiscal 2003, the group discontinued sangui usa and sangui Singapore.
